within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03C_AntispasmodicsInCombinationWithPsycholeptics.A03CB01_MethylscopolamineAndPsycholeptic;

model MethylscopolamineAndPsycholeptic
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.08,
    Cl = 1.0733333333333334e-06,
    adminDuration = 600,
    adminMass = 2.5 / 1000000,
    adminCount = 1,
    Vd = 0.0017,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006666666666666667,
    Tlag = 600);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>MethylscopolamineAndPsycholeptics</td></tr><tr><td>ATC code:</td><td>A03CB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methylscopolamine in combination with psycholeptics is a formulation used primarily for the treatment of gastrointestinal disorders such as peptic ulcer, functional gastrointestinal disorders, and irritable bowel syndrome. Methylscopolamine is an antimuscarinic agent with peripheral anticholinergic effects. The drug combination is not commonly used nowadays, having been replaced by newer agents, and is not widely approved or marketed in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult healthy individuals as published reference PK studies for the combination of methylscopolamine and psycholeptics are lacking; estimates based on single-agent methylscopolamine pharmacokinetics after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03CB01 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MethylscopolamineAndPsycholeptic;
